Illumina escapes genetics trade secrets claims
A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
Idenix angered by confirmation of hepatitis C treatment patent decision
Biopharmaceutical company Idenix has cited the “profound consequences for genus claims” in attacking a federal court ruling to affirm a decision made in a patent dispute with Gilead Sciences.
Eli Lilly to acquire Dermira for $1.1 billion
Global healthcare provider Eli Lilly has agreed to buy Dermira, a biopharmaceutical company, for $1.1 billion, giving it access to a late-stage atopic dermatitis drug and allowing it to challenge Sanofi’s already fully-licenced dupilumab.
HLK adds medical devices expert to Bristol office
Haseltine Lake Kempner has added Jo Deas as a partner to its chemistry and life sciences team, effective January 20.
Breaking: EPO revokes Broad’s CRISPR patent
In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.
Former Genentech employee cuts plea deal with FBI in trade secrets case
A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.
Gilead hit with antitrust suit over HIV drugs
Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.
Breaking: EPO board to refer key issues in Broad appeal to higher panel
The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.
EPO appeals board weighs-up Broad’s CRISPR claims
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
Jennewein takes on Nestlé over baby formula patents
German biotech Jennewein has accused Nestlé Nutrition of infringing patents covering a process of purifying human milk oligosaccharides to make its infant formula.
